BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025

Reuters

2025/09/02

<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025

BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564801581"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564801581\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564801581?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564801581","market":"fut","top_or_hot":-1,"title":"BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-02 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL8D61ww:1","article_id":"2564801581","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564801581","pubTimestamp":1756812641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025. BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research  Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BBIO":"BridgeBio Pharma, Inc.","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4505":"高瓴资本持仓","NDAQ":"纳斯达克OMX交易所","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"BridgeBio Pharma将在2025年ASBMR年会上展示Encaleret治疗术后甲状旁腺功能减退症的有希望的2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BBIO":0.9},"content_text":"BridgeBio Pharma to Present Promising Phase 2 Data for Encaleret in Treating Post-Surgical Hypoparathyroidism at ASBMR Annual Meeting 2025\n    \n\n        BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}